S-2E |
Katalog-Nr.GC67661 |
S-2E ist ein oral aktiver und nicht-kompetitiver HMG-CoA-Reduktase- und Acetyl-CoA-Carboxylase-Inhibitor. S-2E hat eine antihyperlipidämische Wirkung. S-2E hat das Potenzial für die Erforschung von familiärer Hypercholesterinämie und gemischter Hyperlipidämie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 155730-92-0
Sample solution is provided at 25 µL, 10mM.
S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research[1][2].
In the liver, S-2E is converted into its active metabolite, S-2E-CoA. S-2E-CoA noncompetitively inhibits the enzymatic activities of both 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and acetyl-CoA carboxylase at Ki=18.11 μM and Ki=69.2 μM, respectively[1].
S-2E (3-30 mg/kg) given orally suppresses the secretion rate of very-low-density lipoprotein (VLDL)-cholesterol and triglyceride in Triton WR-1339-injected rats. Furthermore, S-2E lowers the blood total cholesterol and triglyceride levels simultaneously in Zucker fatty rats[1].
[1]. Koichi Ohmori, et al. Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. Eur J Pharmacol. 2003 Jun 13;471(1):69-76.
[2]. K Ohmori, et al. Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits. Metabolism. 2004 May;53(5):680-5.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *